Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: New Constructs, LLC
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Faruqi & Faruqi, LLP Announces Investigation Of Potential Securities Fraud At ABIOMED, Inc.


Friday, 9 Nov 2012 10:08pm EST 

Faruqi & Faruqi, LLP, a national securities law firm, is investigating potential securities fraud at ABIOMED, Inc. The investigation focuses on whether the Company and its executives violated federal securities laws by misrepresenting and mislabeling Abiomed's Impella 2.5 heart pump. Abiomed announced on November 1, 2012 that the Washington, D.C. Attorney's Office was conducting an investigation focusing on the marketing and labeling of the Company's Impella 2.5 product. On October 31, 2012, Abiomed accepted service of a Health Insurance Portability and Accountability Act administrative subpoena related to this investigation. The subpoena seeks documents related to the Impella 2.5 and focuses primarily on marketing and labeling issues. Abiomed's announcement follows a June 2011 warning letter from the United States Food and Drug Administration accusing the Company of making unsubstantiated and unauthorized efficacy claims about the Impella 2.5 system in its marketing materials. 

Company Quote

25.18
0.33 +1.33%
3:59pm EDT